The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
about
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phaseSNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis.Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypesChromosome 5q deletion is extremely rare in patients with myelofibrosisDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableDetermination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution.Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.Prognosis of Primary Myelofibrosis in the Genomic EraThe effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 (V617F) positive primary myelofibrosis.Progression of primary myelofibrosis to polycythemia vera: A case report.Emerging therapeutic options for myelofibrosis: a Canadian perspective.New genetic findings in parotid gland pleomorphic adenomas.Prognostication in primary myelofibrosis.3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
P2860
Q33387514-39332809-D4C0-41B5-9201-0F668BD7A2D7Q33392291-991D1946-F150-4381-BE9A-49A988D46D24Q33406990-0AD2F2CF-4A69-49B7-A319-A303C0ACEBF6Q33558154-3D2D53DB-D73E-43B5-B904-2A98DC378D4EQ34081581-0F190223-93F3-4005-85DC-B5A09E669B31Q35265880-DBEBADCB-3ED7-4D7E-822A-957A25487190Q35535523-2AA0FBAD-E920-4628-8264-8CFA47E5AFB0Q36266377-43985703-E10D-453F-87A4-335471A0C5E6Q36502712-66C047DF-E66B-4F3A-AD57-F3DE5339DD50Q36784523-61F01C6D-AB53-4AFD-8ACA-F55AD124C84FQ37163487-0C308124-F20F-4FBF-993A-D49BA50F4147Q38018908-8755FB8C-E9D1-4A7E-A048-6CECA5D2D06FQ38482005-0018B721-7255-49DA-9D32-CCC0B5546E38Q38683077-C986FD35-F241-467D-A258-D4556FAA26F3Q38926804-F825F95B-62AD-4C08-A9FE-CB7DFB3F0BB8Q40197045-F124C919-887C-48D9-B2ED-3DFFFB61E1AAQ41004305-EC30BA8A-8F69-4395-8F72-45126C02DE97Q41049859-D9101EAE-42C8-4235-A1E2-13A5886EF518Q41627599-B08F0D51-F8EA-4C90-ADEF-4A8B07B9FCB0Q43989670-BD0C0A02-F751-40D4-B285-6A9A3872501CQ44731549-072FF18B-91D3-4481-B542-E5EC676BA40BQ50776559-C58766B5-52AE-438B-857F-CA811EDCACDAQ53185401-CC5BA534-3598-46F8-9FD2-5CF320168411Q54794091-674762D7-133D-483F-B16D-94A11A22BAEAQ54981699-C26D85F1-9752-4553-A14D-DBC40B8919A9
P2860
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The role of cytogenetic abnorm ...... nd later during disease course
@en
type
label
The role of cytogenetic abnorm ...... nd later during disease course
@en
prefLabel
The role of cytogenetic abnorm ...... nd later during disease course
@en
P2093
P2860
P50
P1433
P1476
The role of cytogenetic abnorm ...... nd later during disease course
@en
P2093
Alice Lynn
Constantine S Tam
Deborah A Thomas
Katherine I Lin
Lynne V Abruzzo
P2860
P304
P356
10.1182/BLOOD-2008-09-178541
P407
P577
2009-01-08T00:00:00Z